Abstract:Limited success has been achieved in ferroptosis-induced cancer treatment due to the challenges related to low production of toxic reactive oxygen species (ROS) and inherent ROS resistance in cancer cells. To address this issue, a self-assembled nanodrug have been investigated that enhances ferroptosis therapy by increasing ROS production and reducing ROS inhibition. The nanodrug is constructed by allowing doxorubicin (DOX) to interact with Fe 2+ through coordination interactions, forming a stable DOX-Fe 2+ chelate, and this chelate further interacts with sorafenib (SRF), resulting in a stable and uniform nanoparticle. In tumor cells, overexpressed glutathione (GSH) triggers the disassembly of nanodrug, thereby activating the drug release. Interestingly, the released DOX not only activates nicotinamide adenine dinucleotide phosphate oxidase 4 (NOX4) to produce abundant H 2 O 2 production for enhanced ROS production, but also acts as a chemotherapeutics agent, synergizing with ferroptosis. To enhance tumor selectivity and improve the blood clearance, the nanodrug is coated with a related cancer cell membrane, which enhances the selective inhibition of tumor growth and metastasis in a B16F10 mice model. Our findings provide valuable insights into the rational design of self-assembled nanodrug for enhanced ferroptosis therapy in cancer treatment. Statement of significance Ferroptosis is a non-apoptotic form of cell death induced by the iron-regulated lipid peroxides (LPOs), offering a promising potential for effective and safe anti-cancer treatment. However, two significant challenges hinder its clinical application: 1) The easily oxidized nature of Fe2+ and the low concentration of H 2 O 2 leads to a low efficiency of intracellular Fenton reaction, resulting in poor therapeutic efficacy; 2) The instinctive ROS resistance of cancer cells induce drug resistance. Therefore, we developed a simple and high-efficiency nanodrug composed of self-assembling by Fe 2+ sources, H 2 O 2 inducer and ROS resistance inhibitors. This nanodrug can effectively deliver the Fe 2+ sources into tumor tissue, enhance intracellular concentration of H2O2, and reduce ROS resistance, achieving a high-efficiency, precise and safe ferroptosis therapy.

Ultra-small FePt/siRNA loaded mesoporous silica nanoplatform to deplete cysteine for enhanced ferroptosis in breast tumor therapy

Targeted Gsh-Exhausting And Hydroxyl Radical Self-Producing Manganese-Silica Nanomissiles For Mri Guided Ferroptotic Cancer Therapy

A Nanozyme-Based Drug Delivery System to Amplify Ferroptosis Via MET Inhibition and Photodynamic Therapy

Reactive Oxygen-Primed and Autophagy Inhibition-Sensitized Ferroptosis Combined with Photothermal Ablation for Tumor Therapy

GSH/Ph Dual Activatable Crosslinked And Fluorinated Pei for Cancer Gene Therapy Through Endogenous Iron De‐Hijacking And in Situ Ros Amplification

Highly selective and effective ferroptosis liposomal nanodrugs for synergistic antitumor therapy

Manganese-deposited iron oxide promotes tumor-responsive ferroptosis that synergizes the apoptosis of cisplatin

A pH-sensitive imidazole grafted polymeric micelles nanoplatform based on ROS amplification for ferroptosis-enhanced chemodynamic therapy

A Redox‐Triggered Polymeric Nanoparticle for Disrupting Redox Homeostasis and Enhanced Ferroptosis

A tumor microenvironment responsive nanoplatform with oxidative stress amplification for effective MRI-based visual tumor ferroptosis

An Esterase-Responsive SLC7A11 shRNA Delivery System Induced Ferroptosis and Suppressed Hepatocellular Carcinoma Progression

A homologous membrane-camouflaged self-assembled nanodrug for synergistic antitumor therapy

Hijacking cysteine metabolism for reversing hydrogen sulfide production in enhanced ferroptosis therapy

Spatially Asymmetric Nanoparticles for Boosting Ferroptosis in Tumor Therapy.

Ultrasmall Nanoparticles Induce Ferroptosis in Nutrient-Deprived Cancer Cells and Suppress Tumour Growth

Redox Responsive Metal Organic Framework Nanoparticles Induces Ferroptosis for Cancer Therapy

Enhanced ferroptosis therapy with a "nano-destructor" by disrupting intracellular redox and iron homeostasis

A Fe(III)-porphyrin-oxaliplatin(IV) Nanoplatform for Enhanced Ferroptosis and Combined Therapy

A Ph Responsive Nanocomposite for Combination Sonodynamic‐immunotherapy with Ferroptosis and Calcium Ion Overload Via SLC7A11/ACSL4/LPCAT3 Pathway

Membrane Fusion Liposome-Mediated Ferroptosis Explosion for Enhanced Cancer Therapy

Tumor Microenvironment‐Activatable Metal‐Phenolic Nanoformulations for Ultrasound‐Boosted Ferroptosis through Triple Regulatory Pathways